OncoDNA Closes Successful Series B Investment Round
February 14 2020 - 4:00AM
Business Wire
OncoDNA (“OncoDNA or “the Company”), the healthcare technology
company making precision medicine a reality, today announced that
it has completed a €19 million ($20 million) Series B equity
financing. The new funding will support rapid international growth,
accelerate software development and hiring initiatives.
The round was led by Vesalius Biocapital III and Swisscanto
Invest by Zürcher Kantonalbank with the significant support of
SFPI-FPIM. Historical shareholders together with CPH Bank,
Inventures, Sambrinvest, Sofinim (Ackermans & Van Haaren) and
SRIW have also participated. This represents another landmark
achievement after the €8 million Series A fundraising closed in
September 2016.
OncoDNA is now maximizing the fast and proper rollout of its
oncology clinical decision support software OncoKDM® with the
objective of becoming the European leader in oncogenomic data
interpretation and reporting to further support molecular
laboratories, healthcare professionals and the pharma industry in
their daily research and clinical practice.
Jean-Pol Detiffe, Founder & Chief Executive Officer at
OncoDNA: “We are delighted to have successfully raised
sufficient new capital from such quality investors who will enable
us to grow and increase our support to oncologists and cancer
patients with our data driven solutions. OncoDNA is already
positioned as the European champion for cancer precision medicine
as we built a worldwide network of more than several thousand
oncologists. Our next move is to connect molecular laboratories to
our advanced data interpretation tools, which we pride ourselves on
now being possible thanks to the support of our new investors.”
Guy Geldhof, Partner at Vesalius Biocapital III S.C.A. SICAR
said: “We are excited about co-leading the Series B investment
in OncoDNA. It is thrilling to work with a team that has both world
class experience in genomic molecular profiling and a strong desire
to serve patients by offering best-in-class support to oncology
professionals. We are confident OncoDNA will accelerate the
development and commercialization of its valuable new solutions,
especially through closer collaborations with the biopharma
industry, with the final objective of contributing to better
healthcare.”
Robert Schier, Partner at Swisscanto (CH) Private Equity
Switzerland Growth I KmGK added: “OncoDNA has grown
significantly over the past years and are continuing to add the
necessary clinical expertise and know-how to act upon its mission.
Its disruptive vision and highly integrated market approach make it
to be the perfect candidate to rapidly become the European leader
in oncology big data. We are delighted to partner with OncoDNA as
we firmly believe the company contributes to both a more
sustainable healthcare system and improved patient health
outcomes.”
“Considering our important investment in OncoDNA, alongside
players like Vesalius Biocapital III and Swisscanto, we are
convinced that the company has all the necessary means at a key
moment of its development to successfully carry out appropriate
projects to assist and support oncologists in prescribing the most
optimal therapeutic treatments to patients. We are happy to count
on the support of our colleagues from SRIW and Sambrinvest as
historical stakeholders” concluded François Fontaine, at
SFPI-FPIM.
OncoDNA
OncoDNA is a private, oncology-focused healthcare technology
company that combines advanced, comprehensive testing of all
clinically relevant cancer biomarkers (DNA, RNA and protein
profiles) from both solid and liquid biopsies with a proprietary
cancer treatment knowledge database. This one-stop-shop analysis
and interpretation service gives oncologists actionable results to
enable the selection of treatments tailored to the individual
patient’s cancer profile. For laboratories worldwide with NGS
facilities who would like to reach the same level of expertise, we
provide them with state-of-the-art interpretation software to
improve their oncology-oriented analyses routine work. The software
OncoKDM is a web-based tool that processes oncology raw NGS data to
turn data into clinical insight such as treatment options or
clinical trials. OncoDNA also works in collaboration with the
biopharma industry to develop and deliver the treatments of
tomorrow by assisting with design, enrolment and assessment of
clinical trials as well as increasing access to approved precision
medicines. The company is based in Gosselies, Belgium, employs 50
employees in 4 countries, works with an international network of 35
distributors covering approx. 50 countries and is collaborating
with a sub-contracted laboratory of 300 collaborators.
www.oncodna.com
www.vesaliusbiocapital-3.com
www.swisscanto.ch
www.sfpi-fpim.be/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200214005149/en/
OncoDNA Jean-Pol Detiffe, CEO Pierre Flamant, CFO +32 (0)
71 18 35 00